| 37.65 -2.58 (-6.41%) | 10-09 15:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 46.39 |
1-year : | 48.35 |
| Resists | First : | 39.72 |
Second : | 41.4 |
| Pivot price | 38.7 |
|||
| Supports | First : | 37 |
Second : | 30.79 |
| MAs | MA(5) : | 39.15 |
MA(20) : | 38.85 |
| MA(100) : | 37.54  |
MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 51.9 |
D(3) : | 64.7 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 48.45 | Low : | 17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AAPG ] has closed above bottom band by 14.8%. Bollinger Bands are 54.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 40.27 - 40.46 | 40.46 - 40.63 |
| Low: | 38.97 - 39.2 | 39.2 - 39.39 |
| Close: | 39.89 - 40.24 | 40.24 - 40.55 |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Tue, 07 Oct 2025
Ascentage Pharma Engages Investors at October 2025 Conferences - TipRanks
Tue, 07 Oct 2025
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025 - GlobeNewswire
Thu, 02 Oct 2025
Ascentage Pharma appoints Veet Misra as CFO - MSN
Mon, 01 Sep 2025
Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Mon, 01 Sep 2025
Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wed, 20 Aug 2025
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 264 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 17 (K) |
| EPS | -2.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.94 |
| Profit Margin | -296.8 % |
| Operating Margin | -237.1 % |
| Return on Assets (ttm) | -22.8 % |
| Return on Equity (ttm) | -159.7 % |
| Qtrly Rev. Growth | -71.6 % |
| Gross Profit (p.s.) | 3.81 |
| Sales Per Share | 4.2 |
| EBITDA (p.s.) | -11.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -189 (M) |
| Levered Free Cash Flow | 36 (M) |
| PE Ratio | -18.34 |
| PEG Ratio | 0 |
| Price to Book value | 19.27 |
| Price to Sales | 8.9 |
| Price to Cash Flow | -18.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|